Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263198 | 0.91 | F2RL1 (0.40) | ADORA3ADORA2AADORA2BADORA1F2RL1 | |
| SCHEMBL13380079 | 0.79 | LMNA (0.46) | ADORA3ADORA2AADORA2BADORA1F2RL1 | |
| SCHEMBL27316656 | 0.79 | CTSA (0.51) | CTSASMPD3 | |
| SCHEMBL12310928 | 0.79 | NISCH (0.44) | F2RL1PDPK1CASP6HCRTR1HCRTR2 | |
| SCHEMBL2653159 | 0.76 | PDPK1 (0.39) | ADORA2AF2RL1PDPK1CASP6AR | |
| SCHEMBL2652072 | 0.76 | HSP90AA1 (0.41) | ADORA2AADORA1F2RL1METPDPK1 | |
| SCHEMBL17400874 | 0.76 | PDPK1 (0.39) | F2RL1METPDPK1ADRB2CASP6 | |
| SCHEMBL19304124 | 0.75 | ADRB2 (0.43) | ADORA3ADORA2AADORA2BADORA1F2RL1 | |
| SCHEMBL16131407 | 0.74 | PDPK1 (0.42) | ADORA2AADORA1F2RL1PDPK1ADRB2 | |
| SCHEMBL11994379 | 0.73 | PDPK1 (0.57) | ADORA3ADORA2AADORA2BADORA1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-9999619-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ADORA3 3209/4885ADORA2A 2647/4885ADORA2B 3095/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ADORA3 3209/4885ADORA2A 2647/4885ADORA2B 3095/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ADORA3 3209/4885ADORA2A 2647/4885ADORA2B 3095/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ADORA3 3209/4885ADORA2A 2647/4885ADORA2B 3095/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ADORA3 3029/4885ADORA2A 2450/4885ADORA2B 2752/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | ADORA3 3209/4885ADORA2A 2647/4885ADORA2B 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.